企业档案
会员类型：标准版
已获得阿仪网信誉 等级评定
(0 -40)基础信誉积累，可浏览访问
(41-90)良好信誉积累，可接洽商谈
(91+ )优质信誉积累，可持续信赖
阿仪网标准版会员：8年
工商认证 【已认证】
最后认证时间：无需年检
注册号：**** 【已认证】
法人代表：谭春** 【已认证】
参观次数：2676310
技术文章
文献引用产品：人口腔角质形成细胞
点击次数：729 发布时间：2026/5/12 14:38:32
文章标题：Exploring the mechanism of Squamocin inhibits oral squamous cell carcinoma malignant progression by targeting peroxisome proliferator activated receptor-gamma based on network pharmacology and molecular docking
作者列表：Daoyong Hu, Qun Dai, Hao Xiong, Tian Zhong
影响因子：1.6
期刊：Letters in Drug Design & Discovery
发表时间：2026-3-7
DOI:10.1016/j.lddd.2025.100253
文献主题：Abstract
Background
Oral squamous cell carcinoma (OSCC) is a highly ｍmbedstatic malignant tumor that originates from the squamous epithelium of oral mucosa. Squamocin, a compound derived from traditional Chinese medicine, has been shown to inhibit head and neck squamous cell carcinoma, yet its mechanism in OSCC remains unclear.
Methods
Cell functions were assessed using the 3-(4, 5)-dimethylthiahiazo (-z-y1)-3, 5-di-phenytetrazoliumromide (MTT), 5-ethynyl-2’-deoxyuridine (EdU), flow cytometry, transwell, wound healing, and sphere-ｆormation assays. Potential targets of Squamocin in OSCC were predicted via the SwissTargetPrediction and GeneCards databases. A protein-protein interaction (PPI) network was constructed with STRING and visualized in Cytoscape. Gene and protein expression levels were detected by quantitative reverse tranｓcription polymerase chain reaction (qRT-PCR) and western blot. Molecular docking and cell thermal shift assay (CETSA) were used to examine the binding between Squamocin and peroxisome proliferator activated receptor-gamma (PPARG).
原创作者：上海雅吉生物科技有限公司
